Mizuho Securities Cuts Price Target on Teva Pharma (TEVA) Following 2Q Beat
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Mizuho Securities maintained a Buy rating on Teva Pharma (NYSE: TEVA), and cut the price target to $70.00 (from $75.00), following the company's 2Q earnings report. TEVA reported revenue of $5.0B and $1.25 EPS, vs. $4.88B and $1.20 consensus and management's recent guidance of $4.9- $5.0B and $1.19-$1.22. Teva plans to hold an investor event in Sept to highlight its combined generic portfolio, followed by a branded R&D day at the end of the year.
Analyst Irina Koffler commented, "Teva reported a 2Q:16 beat and maintained guidance in spite of adding a distribution business that is expected to contribute $1.0B to its top line. We updated the model for cash/debt and Anda, and lowered our PT to $70 from $75 on these revisions. We still see TEVA as undervalued, with insufficient credit allocated to its pipeline. If the company can prevail in its Copaxone IPR challenge in August, we would expect meaningful share appreciation."
Shares of Teva Pharma closed at $54.21 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Cuts Teva Pharma (TEVA) to Neutral Amid Challenging Generic Environment
- Instinet (Nomura) Downgrades Silicon Motion Technology (SIMO) to Neutral
- Bassett Furniture (BSET) PT Raised to $28 at Stifel Following 4Q EPS Beat
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Related EntitiesEarnings, Irina Koffler
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!